Basia Medical Inc.

What Basia Medical Inc. does

Basia Medical Inc. is a Canadian medical device company developing AI-guided hardware for women's gynecologic care, with a primary focus on cervical cancer screening. Its flagship product, Basia, is an AI-guided, speculum-free device designed to perform cervical examination and tissue sampling without a traditional speculum, targeting the discomfort and accessibility barriers that drive women to delay or skip routine screening. The device uses computer-vision guidance software to help operators locate the correct anatomical position and is engineered so that screening sample quality does not depend on individual operator skill.

The company is led by a three-founder team spanning gynecologic oncology research, clinical practice, and biomedical/AI engineering, supplemented by program administration and research management staff. It maintains strategic collaborations with academic institutions (University of Toronto, Queen's University), a healthcare system partner (Lakeridge Health), and innovation ecosystem organizations (MaRS Discovery District, FemTech Canada, Life Sciences Central, WEMA Inc.) to support device development, clinical evaluation, and commercialization. The intended product strategy is a family of gynecologic devices, with cervical screening as the platform entry point.

Basia Medical is a privately held, founder-controlled company headquartered in Newmarket, Ontario. It is pre-revenue and pre-commercial, with no disclosed funding rounds, pricing, or distribution agreements. Its future revenue model is anchored on hardware sales of AI-guided medical devices to healthcare systems and clinical settings, with go-to-market requiring regulatory clearance, healthcare-provider partnerships, and clinical trial engagements prior to launch.

Name

Basia Medical Inc.

Legal name

Basia Medical Inc.

Website

https://basiamedical.com

Company type

Private

Founded year

2021

Operating status

Operating

Short description

Basia Medical Inc. is a pre-revenue Canadian medical device company developing AI-guided, speculum-free hardware for cervical cancer screening, targeting women who delay or avoid traditional speculum-based exams. The company plans a broader family of AI-guided gynecologic devices beyond cervical screening.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Medical devices
• Cervical cancer screening
• Women's health
• AI-guided diagnostics
• Speculum-free examination

Headquarters

HQ city

Newmarket

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical device sales: As a medical device company with a product in development, Basia Medical will generate revenue through the sale of AI-guided medical devices for cervical cancer screening. The company plans a family of gynecologic health devices beyond the initial cervical screening product.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Basia Medical develops AI-guided medical devices for women's health, with its flagship product being the Basia device—an AI-guided, speculum-free cervical cancer screening device. The device uses computer vision to guide operators to the correct anatomical position and perform standardized sampling without requiring a traditional speculum. The company plans a broader family of gynecologic health devices beyond the initial cervical screening product.

Product overview

Basia Medical Inc. is developing a family of AI-guided medical devices for women's health, starting with cervical cancer screening. The primary product is Basia, an AI-guided, speculum-free device for cervical cancer screening currently in development. Basia uses computer vision guidance to help operators find the correct anatomical location, designed to make screening more comfortable and accessible for women. The company plans to expand this platform approach to other gynecologic health applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Basia An AI-guided, speculum-free medical device for cervical cancer screening. It uses computer vision guidance to help operators locate the correct anatomical position and is designed to perform examination and sampling without a traditional speculum, improving patient comfort and accessibility. It is intended for use by clinicians in healthcare settings performing cervical cancer screening for women.

Quantifiable outcome

• Cervical cancer is among the most preventable cancers when caught early through screening

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, major and supporting.

• Femtech CanadacoreGTM or Marketing Partner · 1 June 2026Basia Medical joined Femtech Canada, the national organization supporting companies advancing innovation in women's health. The partnership provides access to Canada's growing community of founders, researchers, clinicians, and technology companies working to address gaps in women's healthcare.
• Life Sciences CentralcoreStrategic or Co-development Partner · 1 June 2026Basia Medical joined Life Sciences Central, a collaborative initiative led by MaRS Discovery District, OBIO and Toronto Innovation Acceleration Partners. The initiative brings together commercialization resources from Canada's leading health innovation organizations to support high-potential Ontario life sciences companies.
• MaRS Discovery DistrictcoreGTM or Marketing PartnerInnovation hub partner providing access to industry networks, expertise, and commercialization resources for Ontario life sciences companies.
• University of TorontomajorStrategic or Co-development PartnerAcademic institution partner contributing expertise in research and development for medical technology innovation.
• Queen's UniversitymajorStrategic or Co-development PartnerAcademic institution partner contributing research expertise and clinical collaboration capabilities.
• Lakeridge HealthmajorStrategic or Co-development PartnerHealthcare system partner providing clinical expertise and healthcare professional collaboration for device development and evaluation.
• WEMA Inc.supportingOthersNon-profit partner supporting the women's health innovation ecosystem in Canada.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• TruScreen: TruScreen offers a non-visual, real-time cervical screening device that does not require traditional speculum-based cytology, positioning it as a direct technology competitor to Basia's speculum-free screening approach.
• Teal Health: Teal Health is developing a speculum-free, at-home cervical cancer screening solution with a self-collected vaginal sample. It is the closest direct competitor to Basia's speculum-free cervical screening device, addressing the same patient-comfort and access barriers.
• Eve Medical: Eve Medical develops at-home and patient-collected HPV and cervical screening sample collection devices. It overlaps directly with Basia's mission of making cervical screening more comfortable and accessible, particularly outside traditional clinic settings.

Broad incumbents

• Roche Diagnostics: Roche is a leading HPV molecular diagnostics provider (cobas HPV test). Primary HPV screening is increasingly being adopted as a first-line alternative to cytology, directly shaping Basia's competitive landscape.
• CooperSurgical: CooperSurgical supplies a broad portfolio of women's health devices and consumables used in gynecologic exams and procedures, including specula. It represents the incumbent tooling that Basia's speculum-free design seeks to disrupt.
• Hologic: Hologic is the dominant incumbent in cervical cancer diagnostics (ThinPrep Pap Test, HPV assays). Any novel cervical screening device must be validated and commercialized against Hologic's installed base and reimbursement footprint.
• Becton, Dickinson and Company (BD): BD is a major incumbent in women's health and cervical cancer screening (BD SurePath, HPV tests). It competes broadly in the same clinical workflows and is a likely strategic comparator for any new cervical screening entrant.

Emerging players

• MobileODT: MobileODT applies AI and smart imaging (the EVA System colposcope) to cervical cancer screening. It overlaps with Basia on the use of AI/computer vision to improve cervical examination accuracy and accessibility.
• DYSIS Medical: DYSIS Medical makes AI-enabled colposcopes that highlight suspicious cervical lesions in real time. It is a comparable cervical-imaging AI player, though focused on the colposcopy step rather than screening.
• AOA Dx: AOA Dx is developing early-detection diagnostics for women's cancers, including ovarian. It is an emerging femtech/diagnostics peer operating in adjacent women's oncology detection categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/basia-medical
• Instagraminstagram.com/basiamedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Basia Medical Inc.